Hawaii attorney general sues maker of drug Plavix (Update)

by Jennifer Sinco Kelleher

Hawaii's attorney general is suing the makers of a widely prescribed blood thinner that he says a significant portion of the state's population has difficulty metabolizing.

Attorney General David Louie filed a lawsuit Wednesday against the manufacturers and distributors of Plavix, marketed to work similarly to aspirin to prevent a stroke or heart attack.

Louie says the drugmaker didn't disclose that Plavix would have diminished or no effect on people of East Asian and Pacific Islander ancestry. He says the drug puts them at risk for gastrointestinal bleeding and other complications.

The suit names Bristol-Myers Squibb and Sanofi-Aventis as defendants. In a joint statement, the companies said they won't comment on pending litigation.

Sanofi last year said the U.S. Justice Department was investigating its disclosures to the Food and Drug Administration about different responses to Plavix. It provided no details but said it was cooperating with the probe.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Bristol-Myers, Sanofi revamp Plavix sales alliance (Update)

Oct 03, 2012

(AP)—Bristol-Myers Squibb Co. and France's Sanofi SA said Wednesday that they are restructuring their longtime partnership selling popular heart medications, now that their sales are plunging due to widespread competition ...

FDA warning: some patients cannot process Plavix

Mar 12, 2010

(AP) -- The Food and Drug Administration is adding its strongest warning to the label for Plavix, cautioning that some patients do not respond to the blockbuster blood thinner.

FDA says heartburn drugs can interfere with Plavix

Nov 17, 2009

(AP) -- Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack ...

FDA extends Plavix patent by 6 months to May 2012

Jan 25, 2011

(AP) -- The makers of Plavix, the world's second best-selling medication, said Tuesday they will retain exclusive U.S. marketing rights to the blood thinner for an additional six months, under a decision by U.S. health regulators.

Recommended for you

FDA to start regulating lab-developed tests

19 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments